Sanofi’s trial of sutimlimab meets primary and secondary endpoints
CAD is a rare blood diseas where a part of the body’s immune system mistakenly attacks a person’s own healthy red blood cells. Credit: National Institutes of Health.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more